Tempus AI, Inc. And Predicta Biosciences Announce Collaboration To Expand Life Sciences Access To Ultrasensitive Whole-Genome Sequencing Assay For Hematologic Malignancies And MRD Monitoring

Published: 2026-04-15 10:35:56 ET TEM

Published on 04/15/2026 at 10:35 am EDT

Tempus AI, Inc. and Predicta Biosciences announced the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta?, intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring. GenoPredicta is an ultrasensitive assay that extracts deep genetic insights from peripheral blood or bone marrow. By integrating flow cytometry for precise tumor cell detection and enumeration with WGS, the assay delivers a comprehensive analysis of a cancer genome.

It identifies genetic alterations (SNVs/indels, CNVs, SVs)?from as few as 50 tumor cells, corresponding to a sensitivity as low as one in a million cells?to aid in diagnosis, risk classification, and the identification of therapy resistance mechanisms. This sensitivity expands testing eligibility to cases with low tumor burden. The assay is currently available to Tempus? Life Sciences partners to support exploratory research and clinical development programs. The assay has been clinically validated in Multiple Myeloma and other plasma cell dyscrasias and is available for research use only across other indications.

The technology powering the assay stems from the foundational work of Predicta scientific co-founder Dr. Irene Ghobrial, whose research redefined early detection and intervention in blood cancers.